On the heels of a first quarter sales dip, leaders remain confident in Globus Medical’s full-year success, according to a May 8 earnings call. 1. Globus Medical’s Excelsius robotic technologies are ...

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Globus Medical (GMED) to $80 from $100 and keeps an Overweight rating on the ...

Discover key Q1 2025 insights from Globus Medical, including revenue trends, the Nevro acquisition, free cash flow growth, and future strategies.

Globus Medical now expects adjusted per-share earnings of $3 to $3.30 for the year, down from a prior outlook of $3.10 to $3.40. It backed its full-year sales forecast of $2.8 billion to $2.9 billion.

For the quarter ended March 2025, Globus Medical (GMED) reported revenue of $598.12 million, down 1.4% over the same period last year. EPS came in at $0.68, compared to $0.72 in the year-ago quarter.

Globus Medical expects full-year earnings in the range of $3 to $3.30 per share, with revenue in the range of $2.8 billion to $2.9 billion. This story was generated by Automated Insights ( ...